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Translational Relevance 
Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) lack effective 
therapy. Synthetic alkyl-lysophospholipid analogs (ALPs) constitute a family of 
promising anticancer drugs, including miltefosine, perifosine, edelfosine and 
erucylphosphocholine, that promote apoptosis in a variety of tumor cells. Here, we have 
found that edelfosine behaves as the most potent ALP in inducing cell death in MCL 
and CLL cells through co-clustering of Fas/CD95 and rafts. Edelfosine induced a higher 
apoptotic response than perifosine in MCL and CLL patient-derived cells. Oral 
administration of edelfosine showed a strong in vivo anti-MCL and anti-CLL activity in 
xenograft mouse models. The drug accumulated in a dramatic and preferential way in 
the tumor, leading to drastic tumor regression. Our data reported here show a rather 
selective action of edelfosine against tumor cells, and provide the proof-of-principle and 
rationale for further clinical evaluation of edelfosine to improve patient outcome in 
MCL and CLL. 
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Abstract 
Purpose: Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) 
remain B-cell malignancies with limited therapeutic options. The present study 
investigates the in vitro and in vivo effect of the phospholipid ether edelfosine (1-O-
octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) in MCL and CLL. 
Experimental design: A number of cell lines, patient-derived tumor cells and 
xenografts in severe combined immunodeficiency (SCID) mice were used to examine 
the anti-MCL and anti-CLL activity of edelfosine. Furthermore, we analyzed 
edelfosine’s mechanism of action and drug biodistribution in MCL and CLL tumor-
bearing SCID mice. 
Results: Here we have found that the phospholipid ether edelfosine was the most potent 
alkyl-lysophospholipid analog (ALP) in killing MCL and CLL cells, including patient-
derived primary cells, while sparing normal resting lymphocytes. ALPs ranked 
edelfosine > perifosine >> erucylphosphocholine ≥ miltefosine, in their capacity to elicit 
apoptosis in MCL and CLL cells. Edelfosine induced co-clustering of Fas/CD95 death 
receptor and rafts in MCL and CLL cells. Edelfosine was taken up by malignant cells, 
whereas normal resting lymphocytes hardly incorporated the drug. Raft disruption by 
cholesterol depletion inhibited drug uptake, Fas/CD95 clustering and edelfosine-
induced apoptosis. Edelfosine oral administration showed a potent in vivo anticancer 
activity in MCL and CLL xenograft mouse models, and the drug accumulated 
dramatically and preferentially in the tumor. 
Conclusions: Our data indicate that edelfosine accumulates and kills MCL and CLL 
cells in a rather selective way, and set co-clustering of Fas/CD95 and lipid rafts as a 
new framework in MCL and CLL therapy. Our data support a selective antitumor action 
of edelfosine. 
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Introduction 
Chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL) are two major 
B-cell-derived neoplasias for which current therapy is not satisfactory, leading in most 
cases to relapse and eventually to a fatal outcome. This lack of efficient therapy 
underscores the need for a continued search for novel chemotherapeutic agents. CLL is 
the most common adult leukemia and is characterized by the progressive accumulation 
of mature CD5+ B-lymphocytes in the peripheral blood, bone marrow and secondary 
lymphoid organs. New treatment combinations have incorporated the use of purine 
analog (fludarabine)-based regimens together with monoclonal antibodies rituximab 
(anti-CD20) and alemtuzumab (anti-CD52), leading to improved complete response 
rates and prolonged progression-free survival, but a long-term survival benefit has not 
been shown (1, 2). MCL is characterized by the chromosomal translocation 
t(11;14)(q13;q32) resulting in the overexpression of cyclin D1 in mature B-lymphocytes 
that have a striking tendency to disseminate throughout the body (3). MCL is an 
aggressive lymphoma with a poor survival outcome and a median survival time of 3.5 
years. Conventional chemotherapeutic regimens have been the standard treatment of 
MCL until the recent incorporation of rituximab, which increases overall survival as 
well as the response rate and duration. The introduction of stem cell transplantation 
improves survival, although this therapeutic modality is only applied to younger and fit 
patients (4). Currently, allogenic bone marrow transplantation represents the only 
therapy with the potential for a curative approach, although associated with a high rate 
of complications (4). Therefore, development of novel therapeutic strategies is urgently 
needed to improve survival in patients with the above B-cell malignancies. In the last 
years, new strategies have been developed that target crucial cellular pathways, and 
proteasome inhibition with bortezomib has recently been approved in 
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relapsed/refractory MCL (5). MCL and CLL cells share a relatively low proliferative 
index and a poor apoptotic rate (6, 7), and therefore the transforming event is likely a 
failure in death regulation rather than a loss of growth control. This implies that a 
therapeutic potential for these diseases may lie in potentiating apoptosis. 
Synthetic alkyl-lysophospholipid analogs (ALPs) constitute a family of 
promising anticancer drugs, including edelfosine, miltefosine, perifosine and 
erucylphosphocholine, that act at the cell membrane level (8-12). The phospholipid 
ether edelfosine [1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, ET-18-
OCH3], considered the ALP prototype, induces selectively apoptosis in tumor cells (13) 
by recruiting Fas/CD95 death receptor in membrane raft clusters (13-18). Edelfosine 
was the first antitumor agent shown to act through lipid rafts (15), and these membrane 
domains have been recently involved in the chemotherapeutic action of some additional 
antitumor agents (17, 19-23). Lipid rafts are membrane microdomains highly enriched 
in cholesterol and sphingolipids, and the proteins located in these microdomains are 
limited in their ability to freely diffuse over the plasma membrane, affecting protein 
function (24). Recent findings suggest that lipid rafts act as scaffolds where Fas/CD95 
and downstream signaling molecules are recruited to trigger apoptosis (16-18, 21, 25). 
On these grounds, we hypothesized that MCL and CLL, showing a defective cell 
death control, could be considered stark examples for the particular proapoptotic 
features of ALPs. Thus, we addressed the possibility that these B-cell malignancies 
could be treated by these agents, and examined the putative involvement of lipid rafts in 
their antitumor action against MCL and CLL. 
 
Materials and methods 
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 Drugs. Edelfosine was from Inkeysa (Barcelona, Spain) and Apointech 
(Salamanca, Spain). Miltefosine was from Calbiochem (Cambridge, MA). Perifosine 
and erucylphosphocholine were from Zentaris (Frankfurt, Germany). 
  
 Cell lines and primary cells. Detailed information on the cell culture conditions 
for human MCL (JVM-2, Z-138) and CLL (EHEB) cell lines, and primary cells from 
CLL and MCL patients is included in Supplementary data. 
 
Apoptosis assay. Quantitation of apoptotic cells was determined by flow 
cytometry as the percentage of cells in the sub-G1 region (hypodiploidy) in cell cycle 
analysis as previously described (26). 
To analyze apoptosis in CLL/MCL patient-derived samples, 5 x 105 cells were 
incubated for 48 h with the indicated agents. Cells were then washed in annexin-binding 
buffer, and incubated in 50 μl annexin-binding buffer with allophycocyanin (APC)–
conjugated anti-CD3 and phycoerythrin (PE)–conjugated anti-CD19 antibodies from 
Becton Dickinson (Mountain View, CA) for 10 min in the dark. Cells were then diluted 
with annexin-binding buffer to a volume of 150 μl and incubated with 1 μl fluorescein 
isothiocyanate (FITC)-labeled annexin V (Bender MedSystems, Vienna, Austria) for 15 
min in the dark. A total of 10,000 stained cells were then analyzed by flow cytometry 
on a FACSCalibur flow cytometer, using CellQuest software (Becton Dickinson).  
 
Western blot. Proteins (50 μg) were separated on 12 % SDS-PAGE and 
transferred onto Immobilon-P membranes (Millipore, Bedford, MA). Membranes were 
probed with anti-cyclin D1 (DCS-6, Cell Signaling Technologies, Beverly, MA) and 
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anti-β-actin (Sigma, St. Louis, MO) antibodies. Antibody binding was detected using 
the ECL detection system (Amersham, Buckinghamshire, UK). 
 
 Confocal microscopy. Cells were settled onto poly-L-lysine-coated slides and 
analyzed with a Zeiss LSM 510 laser scan confocal microscope (Oberkochen, Germany) 
for membrane raft and Fas/CD95 visualization, using FITC-labeled cholera toxin 
(FITC-CTx) B subunit (Sigma) and anti-human Fas/CD95 SM1/1 IgG2a mouse 
monoclonal antibody (Bender Medsystems, Vienna, Austria) followed by CY3-
conjugated antimouse antibody (Pharmacia, Uppsala, Sweden), as described (15). 
Colocalization assays were analyzed by excitation of both fluorochromes in the same 
section. Negative controls, lacking the primary antibody or using an irrelevant antibody, 
showed no staining. 
 
 Edelfosine uptake. Drug uptake was measured as described previously (13) after 
incubating 106 cells with 10 nmol [3H]edelfosine for 2 h in RPMI-1640/10% FBS, and 
subsequent exhaustive washing (six times) with PBS + 2% BSA to eliminate the loosely 
cell surface-bound ether lipid. [3H]edelfosine (specific activity, 42 Ci/mmol) was 
synthesized by tritiation of the 9-octadecenyl derivative (Amersham Buchler, 
Braunschweig, Germany). 
 
 Cholesterol depletion. 2.5 x 105 cells/ml were pretreated with 2.5 mg/ml methyl-
β-cyclodextrin (MCD) for 30 min at 37ºC in serum-free medium. Cells were then 
washed three times and resuspended in complete culture medium before edelfosine 
addition. 
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 Xenograft mouse model. CB17-severe combined immunodeficiency (SCID) 
mice (Charles River laboratories, Lyon, France), kept and handled according to 
institutional guidelines, complying with Spanish legislation under a 12/12 h light/dark 
cycle at a temperature of 22ºC, received a standard diet and acidified water ad libitum. 
CB17-SCID mice were inoculated subcutaneously into their lower dorsum with 107 Z-
138 or EHEB cells in 100 µl PBS and 100 µl Matrigel basement membrane matrix 
(Becton Dickinson). When tumors were palpable, mice were randomly assigned into 
cohorts of 8-10 mice each, receiving a daily oral administration of edelfosine (30 
mg/kg) or an equal volume of vehicle (PBS). The shortest and longest diameter of the 
tumor were measured with calipers at 2-5-day intervals, and tumor volume (mm3) was 
calculated using the following standard formula: (the shortest diameter)2 × (the longest 
diameter) × 0.5. Animals were sacrificed, according to institutional guidelines, when the 
diameter of their tumors reached 3 cm or when significant toxicity was observed. 
Animal body weight and any sign of morbidity were monitored. Drug treatment lasted 
for 21 (MCL) and 34 (CLL) days, and mice were killed 24 h after the last drug 
administration. Then, tumor xenografts were extirpated, measured and weighed, and a 
necropsy analysis involving tumors and distinct organs was carried out. 
 
 Plasma/tissue extraction procedure for edelfosine biodistribution studies. 
MCL- or CLL-bearing SCID mice were treated with a daily oral administration of 
edelfosine (30 mg/kg) for 21 (MCL) or 34 (CLL) days. Twenty-four h after the last drug 
oral administration, blood was collected in EDTA surface-coated tubes and then 
centrifuged at 2000 g for 15 min (4ºC) to collect plasma (100 μl). Then, animals were 
sacrificed, and distinct organs and tumors were collected and weighed. Tissues and 
tumors were homogenized in 1-ml PBS (pH 7.4) using a Mini-bead Beater (BioSpect 
 9 
Products, Inc., Bartelsville, Oklahoma, USA) and centrifuged at 10000 g for 10 min. 
Both plasma and tissue supernatants were collected and stored at -80ºC until high-
performance liquid chromatography-mass spectrometry (HPLC-MS) analysis was 
performed. Ten μg of platelet activating factor (1 mg/ml), used as internal standard, 
were added onto 100 μl of plasma or tissue/tumor supernatant. 190 μl of a mixture of 
1% formic acid/methanol were added in order to precipitate proteins. Samples were 
vortexed for 1 min and, after centrifugation (20000 g, 10 min), 25 μl of the supernatant 
were analyzed by HPLC-MS. 
 
 Quantitative determination of edelfosine by HPLC-MS analysis. The technique 
used was a slight modification of a previously described method (27), and is described 
in detail in Supplementary data. 
 
 Statistical analysis. All values are expressed as means ± SE. Between-group 
statistical differences were assessed using the Mann-Whitney test or the Student’s t-test. 
A p value of less than 0.05 was considered statistically significant. 
 
Results 
 Edelfosine is the most potent ALP inducing apoptosis in MCL and CLL cells. 
We have previously found that the ALP edelfosine is effective in inducing apoptosis in 
a number of leukemic cells through the aggregation of Fas/CD95 in clustered rafts (14-
18). Following time-course (Fig. 1A) and dose-response (Fig. 1B) experiments, we 
found that that ALPs ranked edelfosine > perifosine >> erucylphosphoholine ≥ 
miltefosine for their capacity to promote apoptosis, assessed as the percentage of cells in 
the sub-G1 region (28), in MCL (JVM-2, Z-138) and CLL (EHEB) cell lines. Because 
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MCL is characterized by cyclin D1 overexpression, we analyzed cyclin D1 levels by 
Western blot in Z-138 and JVM-2 cells exposed for 1-24 h to 10 μM perifosine or 
edelfosine. As shown in Fig. 1C, we found only a decrease in cyclin D1 protein level in 
Z-138 cells after 24-h treatment. However, we detected the cleavage of the typical 
caspase-3 substrate poly(ADP-ribose) polymerase, as a marker for apoptosis onset, by 
6-h treatment in edelfosine- and perifosine-treated Z-138 and JVM-2 cells (data not 
shown), whereas cyclin D1 protein level remained unaffected (Fig. 1C). It is noteworthy 
that despite the presence of the t(11;14) in both JVM-2 and Z-138 cell lines, JVM-2 
cells harbored a reduced basal cyclin D1 content when compared to Z-138, as assessed 
by protein and mRNA levels (Fig. 1C, and data not shown). Thus, these results suggest 
that cyclin D1 modulation is not involved in edelfosine/perifosine antitumor activity in 
MCL cell lines, and that the decrease in cyclin D1 protein level detected at 24 h (Fig. 
1C) was a consequence rather than a cause in edelfosine- and perifosine-induced 
apoptosis. 
Edelfosine was also more active than perifosine against primary malignant cells 
derived from MCL and CLL patients (Fig. 2). Following a dose-response analysis, we 
found that edelfosine was significantly more cytotoxic (p < 0.05) than perifosine against 
primary CD19+-CLL cells derived from patients, whereas normal resting CD3+-T 
lymphocytes from the same patients remained rather resistant (Table 1). This selective 
action of both edelfosine and perifosine was highlighted when compared to 
staurosporine that induced apoptosis in both malignant and normal cells at a similar rate 
(Table 1). 
 
 Edelfosine-induced apoptosis in MCL and CLL cells is mediated by lipid rafts. 
By using the raft marker FITC-CTx B subunit that binds ganglioside GM1 (29), mainly 
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found in rafts (30), we found that 10 µM edelfosine induced co-clustering of lipid rafts 
and Fas/CD95 in both JVM-2 and EHEB cells (Fig. 3). Furthermore, we found that 
MCL (JVM-2, Z-138) and CLL (EHEB) cell lines took up high amounts of edelfosine 
(Fig. 4A), whereas normal resting lymphocytes incorporated negligible amounts of drug 
(<20 pmol/106 cells after 2 h of incubation with 10 nmol [3H]edelfosine). Lipid raft 
disruption by MCD treatment inhibited drug uptake (Fig. 4A), edelfosine-induced 
apoptosis (Fig. 4B), as well as Fas/CD95 clustering (data not shown). These data 
suggest that lipid rafts are essential for edelfosine uptake and edelfosine-induced 
apoptosis in MCL and CLL cells. 
 
 Edelfosine accumulates in MCL and CLL tumors and inhibits human MCL 
and CLL cell growth in vivo. We next determined whether edelfosine showed in vivo 
anti-human MCL and CLL cell activity. CB17-SCID mice were inoculated with 107 Z-
138 or EHEB cells for MCL or CLL xenograft animal models. The MCL animal model 
developed aggressive tumors that were tangible within one week of inoculation, and 
increased rapidly in a few weeks time (Fig. 5A), whereas CLL tumors grew more 
slowly (Fig. 5A). Following the development of a palpable tumor, mice were 
randomized into drug-treated (30 mg/kg edelfosine, daily oral administration) and 
control (PBS vehicle) groups. Caliper measurements were performed every 2-5 days to 
calculate tumor volume (Fig. 5A). Oral administration of edelfosine achieved 
significant MCL and CLL tumor regression (Fig. 5, A-C). When tumor size reached 
about 10% of body-weight, animals were killed for ethical reasons. This size was 
approximately reached by day 15 in some of the MCL tumor-bearing mice (Fig. 5A), 
but this animal model was extended one week more in order to obtain reliable and 
comparable data with drug-treated animals in which tumor size was decreased by that 
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time (Fig. 5A). A comparison of tumors isolated from untreated control and drug-
treated MCL- and CLL-bearing mice, at the end of treatment, rendered a remarkable 
anti-MCL and anti-CLL activity of edelfosine, with a reduction of more than 85% in 
tumor weight and volume in both MCL and CLL animal models (Fig. 5B). Organ 
examination at necropsy did not reveal any apparent toxicity (data not shown), and there 
was an evident difference between the highly vascularized tumors from drug-free mice 
and the pale poorly vascularized tumors from edelfosine-treated mice (Fig. 5C). In 
addition, MCL tumors were bulky in drug-free mice, but resulted rather flat after 
edelfosine treatment (Fig. 5C). No significant differences in mean body weight were 
observed between drug-treated and control animals during the in vivo assay (3-5% of 
body weight loss in the treated groups vs. control groups). A drug biodistribution study 
showed that edelfosine dramatically accumulated in the MCL and CLL tumors (Fig. 
5D). Tumor/plasma concentration ratio of edelfosine in the tumor was significantly 
higher than that detected in both kidney and liver after completion of the experiment in 
MCL and CLL animal models (Fig. 5D), with a drug mean concentration in plasma of 
5.64 µg/ml. In the CLL animal model, we examined the content of edelfosine in a wide 
variety of distinct organs, and found that the drug was dramatically accumulated in the 
tumor as compared to lung, heart, spleen, liver, intestine, or kidney (Fig. 5D). Taking 
together, our data indicate a preferential accumulation of edelfosine in the tumor. 
 
Discussion 
 The data reported here show that edelfosine behaves as the most potent ALP in 
killing MCL and CLL cells via a raft-mediated process. Our data indicate that 
edelfosine is a powerful antitumor agent against MCL and CLL as assessed by in vitro, 
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ex vivo and in vivo evidences. In addition, we found a rather selective and dramatic 
accumulation of edelfosine in MCL and CLL tumor cells in animal models.  
Here we found that edelfosine induces the recruitment of Fas/CD95 death 
receptor in raft aggregates in MCL and CLL cells. Raft disruption by cholesterol 
depletion in MCL and CLL cells inhibited both edelfosine uptake and drug-induced 
apoptosis, as well as Fas/CD95 clustering, thus suggesting a major role of rafts in the 
uptake and antitumor action of edelfosine. Previous reports have shown that MCL and 
CLL cells express Fas/CD95, but a deficient apoptotic response to the external 
stimulation of Fas/CD95 by agonistic anti-Fas/CD95 antibodies was reported (7, 31). 
Unlike the natural ligand FasL/CD95L or agonistic anti-Fas/CD95 antibodies that act 
through their interaction with the exogenous portion of the Fas/CD95 death receptor, 
edelfosine induces activation of Fas/CD95 from within the cell independently of its 
ligand (16, 32). We have previously found that edelfosine is even more efficient than 
FasL/CD95L in promoting programmed cell death through Fas/CD95 activation by its 
recruitment in membrane rafts enriched in downstream signaling molecules (14, 16-18, 
25, 33). Thus, edelfosine might induce Fas/CD95 activation, even though the receptor is 
not triggered by its natural ligand or agonistic antibodies. 
Using distinct MCL and CLL xenograft mouse models, we found that edelfosine 
accumulates in high amounts in the tumor tissue and shows a remarkable antitumor 
activity, leading to dramatic tumor regression. In addition, we consistently found in the 
MCL and CLL xenograft animal models that tumors became smaller and poorly 
vascularized. This could be in agreement with reports showing an antiangiogenic effect 
of edelfosine (34, 35). Thus, further insight into the effect of edelfosine on angiogenesis 
and how this action affects cancer development is warranted. 
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Following edelfosine oral administration in non-tumor-bearing SCID mice, we 
have recently found a rather wide drug distribution pattern to several tissues, including 
lung, spleen, intestine, liver and kidney (36). In this study, we also found that edelfosine 
showed a preferential accumulation in the tumor in a MCL-bearing mouse animal 
model (36). Now, we have largely extended this initial study and analyzed the in vivo 
effect of edelfosine in MCL and CLL animal models. Interestingly, we found here that 
when SCID mice contained a MCL or CLL tumor, edelfosine distribution was 
dramatically and significantly shifted towards the tumor (tissue/plasma concentration 
ratios >16; p < 0.01), suggesting a preferential tumor location for edelfosine. Our herein 
reported in vivo data, together with our present and previous in vitro determinations in a 
wide number of malignant and normal cells (14, 16, 17), suggest a rather selective 
edelfosine uptake and cytotoxic action in tumor cells. The selective action of edelfosine 
on tumor cells supports its low toxicity. We did not find any apparent damage in the 
distinct organs analyzed following necropsy analysis in the in vivo studies reported here. 
Lack of toxicity of edelfosine in a rat model has been reported, including no significant 
cardiotoxicity, hepatotoxicity or renal toxicity (37). Our biodistribution data in the 
murine models reported here showed a mean concentration of edelfosine in plasma of 
5.64 µg/ml (10.77 µM; edelfosine molecular mass, 523.7). Thus, the herein reported in 
vitro effects, rendered by 10 µM edelfosine, were detected at a pharmacologically 
relevant drug concentration. 
Our data constitute the first in vitro and in vivo evidence for the antitumor action 
of edelfosine in MCL and CLL, two hematologic malignancies with poor survival 
outcome. Taken together, the results reported here provide the proof-of-principle and 
rationale for further clinical evaluation of edelfosine to improve patient outcome in 
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MCL and CLL. The results reported here also highlight the involvement of lipid rafts in 
the action of edelfosine on B-cell malignancies, such as MCL and CLL. 
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FIGURE LEGENDS 
 
Fig. 1. Induction of apoptosis in MCL and CLL cells by ALPs. MCL (JVM-2, Z-138) 
and CLL (EHEB) cell lines were incubated for the indicated times with 10 µM of the 
distinct ALPs edelfosine, perifosine, miltefosine and erucylphosohocholine (erucyl-PC) 
(A), or for 24 h with different concentrations of the ALPs (B). Apoptosis was then 
quantitated as percentage of cells in the sub-G1 region by flow cytometry. Untreated 
control cells were run in parallel. Data shown are means ± SE of 4 independent 
determinations. (C) Cells were untreated or treated with 10 µM perifosine or edelfosine 
for the indicated times, and analyzed by Western blot with anti-cyclin D1 and anti-β-
actin antibodies. Immunoblotting of β-actin was used as an internal control for equal 
protein loading in each lane. Blots are representative of three experiments performed. 
 
Fig. 2. Edelfosine and perifosine kill patient-derived MCL and CLL cells. Primary 
malignant cells isolated from MCL and CLL patients were incubated for 48 h in the 
absence (control) or in the presence of 10 µM edelfosine (EDLF) or perifosine (PERF), 
and then cell viability was assessed as nonapoptotic cells in annexin V analysis by flow 
cytometry. Data shown are means ± SE of 7 (MCL) or 10 (CLL) independent patients. 
Asterisks indicate that cell viability in edelfosine- and perifosine-treated cells is 
significantly different from untreated control cells at p < 0.05 (*) and p < 0.01 (**) 
levels by Student’s t-test. 
 
Fig. 3. Edelfosine-induced co-clustering of Fas/CD95 and rafts in MCL and CLL cells. 
JVM-2 and EHEB cells were either untreated (Control) or treated with 10 μM 
edelfosine for 9 h, and then stained with FITC-CTx B subunit to identify lipid rafts 
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(green fluorescence) and with a specific anti-Fas/CD95 monoclonal antibody, followed 
by CY3-conjugated anti-mouse Ig antibody (red fluoresecence). Areas of colocalization 
between membrane rafts and Fas/CD95 in the merge panels are yellow. Images shown 
are representative of 4 independent experiments. Bar, 10 μm. 
 
Fig. 4. Raft involvement in edelfosine uptake and edelfosine-induced apoptosis. (A) 
JVM-2, Z-138 and EHEB cells, untreated or pretreated with 2.5 mg/ml MCD for 30 
min, were incubated with 10 nmol [3H]edelfosine (0.1 µCi) for 2 h, and then drug 
uptake was determined. (B) JVM-2, Z-138 and EHEB cells, untreated or pretreated with 
2.5 mg/ml MCD for 30 min, were incubated with 10 µM edelfosine for 24 h, and then 
apoptosis was assessed by flow cytometry as the percentage of hypodiploid (sub-G1) 
cells. Data shown are means ± SE of 4 independent determinations. Asterisks indicate 
values that are significantly different from the corresponding MCD-untreated cells at p 
< 0.05 (*) and p < 0.01 (**) levels by Student’s t-test. 
 
Fig. 5. Edelfosine inhibits human MCL and CLL cell growth in vivo. CB17-SCID mice 
were incoculated s.c. with 107 Z-138 or EHEB cells. Daily oral administration of 
edelfosine (30 mg/kg, n = 10 for MCL animal model, and n = 8 for CLL animal model) 
started after the development of a palpable tumor. Tumor size was recorded every 2-5 
days. (A) Edelfosine (EDLF) significantly (p < 0.01; from day 15 of treatment until the 
end of the experiment) inhibited MCL and CLL tumor growth compared to the control 
group treated with vehicle (PBS, n = 10 for MCL animal model, and n = 8 for CLL 
animal model). Data shown are means ± SE (n = 10, MCL; n = 8, CLL). (B) After 
completion of the in vivo assay (22 days for MCL, and 35 days for CLL), control and 
edelfosine-treated mice were sacrificed and tumors were measured in the distinct mice. 
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The tumor size and weight values of each single animal (dots) and the average values of 
each experimental group (horizontal bars) are shown. Asterisks indicate that tumor 
weight and size values were significantly lower after edelfosine treatment, as compared 
to control drug-free mice, at p < 0.01 (**). (C) Remarkable growth inhibition of MCL 
and CLL tumors were observed after edelfosine treatment (30 mg/kg). (D) 
Tissue/plasma concentration ratios, in liver, kidney and tumor, of edelfosine after daily 
oral administration of edelfosine (30 mg/kg) for 3 weeks in MCL-bearing SCID mice 
(mean ± SE, n = 5), and tissue/plasma concentration ratios, in lung, heart, spleen, liver, 
intestine, kidney and tumor, of edelfosine after daily oral administration of edelfosine 
(30 mg/kg) for 34 days in CLL-bearing SCID mice (mean ± SE, n = 5). Asterisks 
indicate that the tumor/plasma ratio values are significantly different from the other 
tissue/plasma ratios at p < 0.01 (**). 
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Table 1. Selective killing of patient-derived CLL cells by edelfosine, sparing normal 
cells.  
 
 % Cell viability 
Treatment CD19+-CLL cells CD3+-T cells 
Edelfosine (10 µM) 60.3 ± 5.6 97.8 ± 1.9 
Edelfosine (20 µM) 43.7 ± 4.9 86.5 ± 3.2 
Perifosine (10 µM) 73.1 ± 4.8 98.4 ± 1.5 
Perifosine (20 µM) 61.0 ± 3.7 90.9 ± 2.8 
Staurosporine (0.5 µM) 17.8 ± 6.7 22.5 ± 7.5 
 
Primary lymphocyte cultures from CLL patients were incubated with edelfosine or 
perifosine for 48 h at the indicated concentrations. Staurosporine was used as a positive 
control of apoptosis. Percentage of cell viability was measured as nonapoptotic 
CD3+/CD19- T cells or CD3-/CD19+ B cells from CLL samples in annexin V analysis 
by flow cytometry. Untreated control CD19+ and CD3+ cells were run in parallel, and 
showed a cell viability >93% and >98%, respectively. Data are shown as mean values ± 
SE of 5 independent CLL patients. 
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Figure 1 
Mollinedo et al. 
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Figure 2 
Mollinedo et al. 
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Figure 3 
Mollinedo et al. 
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Figure 4 
Mollinedo et al. 
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Figure 5 
Mollinedo et al. 
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